Kira Pharma closed a $53.5 million Series B+ financing to develop complement-targeted therapies that treat immune-mediated diseases. Kira is headquartered in Cambridge , MA with R&D operations in Suzhou . The company. which described the oversubscribed round as a first closing, expects to start clinical trials of three complement-targeted therapies in the next 18 months. The financing was co-led by RA Capital Management  and Vivo Capital. More details.... Share this with colleagues: // //